Several combination therapies have been proposed for BRAF resistance in EGFR-mutant lung cancer, but an integrated genomic analysis of these tumors is lacking and precludes an optimization of therapeutic regimen24–27. The gene discussed is BRAF; the disease is lung carcinoma.